Sen. Jim Banks (R-Ind.) wants the Food and Drug Administration to look into foreign-made active pharmaceutical ingredients he ...
Is the era of sourcing cheaper weight loss drugs from the internet over? High demand for GLP-1 agonists — prescription drugs ...
MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...
GLP-1 drugs have revolutionised the treatment of obesity, but the very reason they are effective is also why it's vital to prioritise exercise when taking them ...
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm ...
Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight loss drugs Mounjaro ... telehealth company Hims & Hers says the new ...
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
was curious about the ads he saw promising to reverse his hair loss. He completed a 14-question intake on Hims.com and received a bottle of finasteride pills days later. He never spoke to a doctor.
Hims & Hers' lower-priced injectable semaglutide promoted during the Super Bowl has led to some patients receiving the more affordable metformin instead. Originally sourced from lilacs, metformin ...
showed participants experienced sustained weight loss. People with class 1 obesity lost on average 6.3% of their total body weight. Sirona is a dual-polymer hydrogel pill that expands in the stomach, ...
Hims & Hers is set to continue offering weight-loss pills and personalized weight-loss support, including nutrition plans and coaching. Outside of weight-loss care, the company saw its subscriber ...
Hims & Hers’ weight loss offerings will now mainly include its oral medications and the liraglutide injection, which the company plans to launch in the early second half of 2025. Also ...